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Abstract
The pyrrolopyrimidine U101033E is a therapeutic compound potentially useful in stroke, head injury and other oxidative
stress conditions. Electron paramagnetic resonance (EPR) techniques of spin labeling and spin trapping in conjunction with
measures of lipid and protein oxidation have been used to investigate the proposed antioxidant capacity of U101033E. We
report potent antioxidant activity of this agent in aqueous cell-free solution as measured by spin trapping. U101033E
significantly (P6 0.005) reduces the formation of the EPR active spin trap N-t-butyl-K-phenylnitrone (PBN)-radical adduct
by 17.1% at a concentration of 1 WM, four orders of magnitude less than the concentration of PBN. As measured by the
decrease in signal intensity of lipid-resident nitroxide stearate spin probes, an EPR assay for lipid peroxidation, this
pyrrolopyrimidine compound efficiently protected against hydroxyl radical-induced lipid peroxidation in cortical
synaptosomal membranes deep within the membrane bilayer, but not closer to the membrane surface. In addition,
U101033E partially prevents synaptosomal protein oxidation in the presence of Fe(II) ; however, U101033E demonstrates
some protein oxidative effects itself. These results are supportive of the proposed role of U101033E as a lipid-specific
antioxidant, especially for protection against lipid peroxidation that occurs deep within the membrane bilayer, but raise some
potential concerns about the oxidative nature of this agent toward proteins. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Increasing evidence continues to implicate oxida-
tive stress in the neurodegenerative cascades linked
to various central nervous system (CNS) disorders.
Neuronal dysfunction associated with disorders such
as Alzheimer’s disease (AD) and following an insult
such as ischemia/reperfusion has been found to cor-
relate with oxidative damage in clinical and model
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Abbreviations: EPR, electron paramagnetic resonance; HNE,
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fate^polyacrylamide gel electrophoresis ; DNP, dinitrophenylhy-
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systems [1^3]. Antioxidants are reported to o¡er pro-
tection against oxidative damage in these disorders
[4^9].
Among major biomarkers for oxidative damage
are lipid peroxidation products, especially 4-hy-
droxy-2-trans-nonenal (HNE), which is thought to
play an important role as a mediator of free radi-
cal-induced neurotoxicity [10]. The amyloid-beta-
peptide (AL), found as the major constituent of senile
plaques in the AD brain, has been shown to generate
free radicals [11^13] and thus contributes to the oxi-
dative stress environment found in the AD brain. AL
initiates lipid peroxidation that leads to HNE forma-
tion [14,15], which has been suggested to mediate the
toxic e¡ects of the peptide [15^18]. Increased levels of
free and bound HNE have been found in the AD
brain and cerebro-spinal £uid (CSF) [19^23]. Free
radical-induced lipid peroxidation has also been
shown to be responsible for much of the damage
incurred after an ischemic insult [24], as well as in
other disorders [25]. Diminished lipid damage follow-
ing the administration of lipophilic antioxidants re-
sults in neuroprotection [1,5,26^29], suggesting the
importance of these free radical scavengers in neuro-
nal injury. Studies such as these further promote the
role of lipid peroxidation products, especially HNE,
in the neurodegenerative cascade.
That oxidative lesions and lipid peroxidation prod-
ucts are increased in neurological disorders and that
antioxidants have been shown to diminish the forma-
tion of both suggests that antioxidative therapeutics
may be bene¢cial in these disorders. Protection of
neuronal membranes by lipophilic antioxidants
would quench the initiation of the oxidative process
and eliminate any resulting damage. Preincubation
with antioxidants such as vitamin E, estrogen and
glutathione has provided protection against radical-
induced injury [5,8,9,28^30]. The pyrrolopyrimidines
are a relatively new class of proposed therapeutics
for the prevention of free radical-induced damage,
especially lipid peroxidation. In several models of
oxidative stress-induced cellular injury, including is-
chemia/reperfusion, a pre-administration of the pyr-
rolopyrimidines, especially U101033E (Fig. 1), has
resulted in signi¢cantly diminished neuronal damage
[1,26,27,31^38].
In the current study, the means by which
U101033E mediates its protective e¡ects were inves-
tigated. The free radical scavenging capabilities of
U101033E were determined using an aqueous elec-
tron paramagnetic resonance (EPR) spin trapping
assay. Protection from hydroxyl free radicals by
U101033E was also investigated in cortical synapto-
somal preparations. Oxidative modi¢cations of syn-
aptosomal proteins by hydroxyl radicals, manifested
as protein carbonyls and the induction of protein
conformational changes were examined by Western
immunoblotting and EPR spin labeling techniques,
respectively. In addition, U101033E was tested for
its ability to quench hydroxyl radical-induced lipid
peroxidation in synaptosomal membranes by moni-
toring the EPR signal intensity of the lipid-speci¢c
spin probes, 5-nitroxide stearate (NS) and 12-NS.
2. Materials and methods
2.1. Chemicals
Protease inhibitors were purchased from ICN.
U101033E was a generous gift from E.D. Hall
(then at Pharmacia-Upjohn). An Oxyblot kit was
obtained from Encor. PBN (N-t-butyl-K-phenylni-
trone) was synthesized as described by Huie et al.
[39], repeatedly recrystallized and sublimed and pu-
rity demonstrated by high performance liquid chro-
matography, nuclear magnetic resonance and EPR.
Nitrocellulose membranes and transfer ¢lter papers
were purchased from Bio-Rad. All other chemicals
were obtained from Sigma in highest purity.
2.2. Synaptosomal preparation
Synaptosomes were prepared as described previ-
ously [40]. Gerbils were decapitated, the brain re-
Fig. 1. The structure of the pyrrolopyrimidine U101033E.
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moved quickly and put on ice. Each cortex was dis-
sected and immediately suspended in ice-cold isola-
tion bu¡er containing: 0.32 M sucrose containing
4 Wg/ml leupeptin, 4 Wg/ml pepstatin, 5 Wg/ml aproti-
nin, 20 Wg/ml trypsin inhibitor, 0.2 mM phenyl meth-
yl sulfonyl £uoride (PMSF), 2 mM ethylenediamine
tetraacetic acid (EDTA), 2 mM ethyleneglycol biste-
traacetic acid (EGTA) and 20 mM 4-(2-hydroxyyeth-
yl)-1-piperazineethane sulfonic acid (HEPES). All
cortices were then homogenized by 12 passes with a
motor driven te£on pestle. The homogenate was cen-
trifuged at 3800 rpm (1500Ug) for 10 min. Discard-
ing the pellet, the supernatant was collected and cen-
trifuged at 14 800 rpm (20 000Ug) for 10 min. The
supernatant was removed and the pellet resuspended
in isolation bu¡er. This resuspension was layered
onto discontinuous gradients containing 10 ml each
of 1.18, 1.0 and 0.85 M sucrose solutions each with
2 mM EDTA, 2 mM EGTA and 10 mM HEPES
(pH 8.0 for 0.85 and 1.0 M solutions, pH 8.5 for
1.18 M solution). Samples were spun in a Beckman
L7-55 ultracentrifuge at 22 000 rpm (82 500Ug) for
2 h at 4‡C. The resulting puri¢ed synaptosomal
vesicles were removed from the 1.18/1.0 M interface
and subsequently lysed and washed twice with lysing
bu¡er (2 mM EDTA, 2 mM EGTA, 10 mM HEPES,
pH 7.4). All centrifugations were performed at 4‡C.
The total protein concentration was determined by
the method of Lowry et al. [41] and all samples were
adjusted to a concentration of 4 mg/ml.
2.3. EPR and spin trapping
PBN was used as the spin trap in an aqueous spin
trapping assay. PBN was dissolved in H2O as a 50
mM stock solution, with a 10 mM ¢nal concentra-
tion in all samples. The Fenton reaction was used as
the radical generating system with ¢nal concentra-
tions of Fe(II) and H2O2 being 30 WM and 3 mM,
respectively. All reagents, except hydrogen peroxide,
were added, the samples were vortexed to ensure
complete mixing and were again vortexed after the
addition of hydrogen peroxide. Each reaction was
allowed to incubate for 30 min at room temperature
before being stopped with the addition of 2 mM
deferoxamine, an iron ion-chelating reagent.
U101033E was added in volumes of 10 Wl from stock
solutions of 100, 10, 1 and 0.1 mM in dimethyl sulf-
oxide (DMSO), giving ¢nal concentrations of 1, 0.1,
0.01 and 0.001 mM, respectively. All control samples
contained 1% DMSO. EPR spectra were acquired on
a Bruker EMX spectrometer with the following in-
strumental parameters: microwave frequency, 9.77
GHz; microwave power, 20 mW; receiver gain,
1U105 ; modulation amplitude, 0.3 G and time con-
stant, 1.28 ms.
2.4. Oxidative treatment and spin labeling
For protein oxidation studies, samples were
treated with U101033E or the corresponding volume
of vehicle (DMSO), mixed gently and incubated for
30 min at room temperature. The samples were then
divided into two equal portions and oxidants added
to one portion and the corresponding volume of
bu¡er added to the second portion. Oxidation was
accomplished by addition of 30 WM Fe(II) to synap-
tosomes, which contain intrinsic H2O2 [42] and 3 mM
ascorbic acid, to keep Fe(II) in the reduced state.
Samples were again mixed gently and incubated at
room temperature. After 30 min, the samples were
washed three times in lysing bu¡er to remove excess
oxidants. For all dose response studies, U101033E
was incubated in synaptosomes at room temperature
for 1 h.
Following oxidative treatments, samples were an-
alyzed for changes in protein conformation by EPR
after being labeled with the paramagnetic protein-
speci¢c spin label Mal-6 (2,2,6,6-tetramethyl-4-male-
imidopiperidin-1-oxyl) [43^46]. Mal-6 (2.5 mg) was
dissolved in 100 Wl of acetonitrile and diluted to 50
ml in lysing bu¡er. Samples were labeled by incubat-
ing 12.5 Wg Mal-6/mg of protein ([50 WM] ¢nal con-
centration) for 16 h at 4‡C [46]. Samples were pel-
leted in a refrigerated Eppendorf table-top
centrifuge, the supernatant removed and the pellet
resuspended in 1 ml of fresh lysing bu¡er. This wash-
ing cycle was repeated six times to ensure complete
removal of all unbound spin label before acquiring
EPR spectra.
The analysis of lipid peroxidation was performed
in conjunction with the lipid-speci¢c spin probes, 5-
NS and 12-NS. Samples were incubated for 1 h at
room temperature by gentle shaking in culture tubes
coated with 6 Wg of 5- or 12-NS/mg of protein. The
samples were then taken for EPR analysis as indi-
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cated above. Following acquisition of the initial spec-
trum, each sample was removed from the quartz £at
cell for aqueous samples and mixed with Fe(II) (30
WM), U101033E or vehicle. In samples receiving
treatment with U101033E (or vehicle) and Fe(II),
the former was incubated for 30 min prior to addi-
tion of Fe(II). The sample was mixed and immedi-
ately returned to EPR in order to monitor the de-
crease of signal intensity with time.
2.5. Western blotting
Protein carbonyls are an index of protein oxida-
tion [47]. The method of detection in this study was
by Western blot analysis of the 2,4-dinitrophenyl hy-
drazone (DNP) adduct of the carbonyls. Sample ali-
quots (30 Wg protein) were incubated with 2,4-dini-
trophenylhydrazine in the presence of SDS for 20
min at room temperature and quenched by the addi-
tion of a neutralization solution. Proteins were sep-
arated by non-reducing SDS^PAGE according to
Laemmli et al. [48] using 4.6 and 12.5% acrylamide
stacking and separating gels, respectively. Care was
taken to load the same amount of protein to each
lane on the gel and protein amounts in each lane
were determined by Coomassie staining. Proteins
were electroblotted onto a nitrocellulose membrane
and analyzed colorimetrically by employing a rabbit
antibody speci¢c for 2,4-dinitrophenylhydrazone
protein adducts and an alkaline-phosphatase conju-
gated IgG (goat anti-rabbit) using BCIP/NBT as
substrate. Levels of DNPH reactivity were digitized
and quantitated using computer-assisted imaging
with MCID/M4 software supplied by Imaging Re-
search (St. Catharine’s, Ont., Canada).
3. Results
3.1. Spin trapping
The EPR method of spin trapping involves the use
of an EPR-silent ‘spin trap’ and some source of tran-
sient free radicals (reviewed in [49,50]). In our spin
trapping assay, PBN was used as the trap while Fen-
ton chemistry was used to generate hydroxyl radi-
cals. The reaction of radicals with the nitrone spin
trap produces EPR active nitroxide spin adducts.
The spin adducts are much more stable than their
short-lived parent radicals and can therefore be
quantitated by EPR spectroscopy.
These spin trapping methods were used to deter-
mine directly the free radical scavenging ability of
U101033E and for this reason were performed in
an aqueous cell-free system containing only the ni-
trone trap, the radical generating system and the
drug or vehicle. In all spin trapping experiments con-
ducted, the DMSO was held constant (1%). In the
absence of U101033E, a 6-line EPR spectrum is ob-
served (AN = 15.08 G, AH = 3.38 G) which is compar-
Fig. 2. The pyrrolopyrimidine U101033E dramatically decreases
the EPR signal from PBN-radical adducts. (A) EPR signal re-
sulting from a 30 min incubation of 10 mM PBN, vehicle (1%
DMSO) and Fenton chemistry-produced hydroxyl radicals. (B)
An 81.8% decrease in signal intensity results in the presence of
10 WM U101033E, three orders of magnitude less than the con-
centration of PBN. (C) Increasing concentrations of U101033E
result in the elimination of PBN trapped radicals as shown by
larger % decreases in EPR signal (n = 6; *P6 0.005;
**P6 0.001; Student’s paired t-test).
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able with reports of a PBN-DMSO adduct [51]. A
dramatic decrease in PBN trapped radical, observed
as a decrease in EPR signal intensity of the 6-line
spectrum, was found in the presence of U101033E
(Fig. 2). Concentrations as low as 1 WM resulted in
a signi¢cant reduction (17.1%, P6 0.005) in the EPR
signal intensity. These results indicate the potent
ability of the pyrrolopyrimidine U101033E to scav-
enge radicals.
3.2. Analysis of lipid peroxidation
The reduction of the EPR signal intensity of the
NS spin probes in neuronal membranes has been
used as a model of lipid oxidation and as an assay
for the radical scavenging ability of antioxidant com-
pounds [14,29,52]. The reaction of nitroxide spin
probes with some transient free radical results in
the formation of the non-paramagnetic hydroxyl-
amine and a consequent loss in EPR signal intensity.
The generation of hydroxyl radicals in our experi-
ments with synaptosomes likely leads to the forma-
tion of carbon centered lipid radicals (and the initia-
tion of lipid peroxidation) that can react directly
with nitroxide probes. It is in this sense that the
radical-induced reduction of NS spin probes mimics
lipid oxidation. Radical scavenging compounds that
intercept these radicals (and also lipid peroxyl radi-
cals) before the chemical reduction of the nitroxide
prevent the loss of EPR signal intensity and are
likely to have quenched the lipid peroxidative chain
reaction. 5-NS contains a nitroxide group on the 5th
carbon of the stearic acid acyl chain, whereas the
nitroxide is on the 12th carbon of 12-NS. This selec-
tivity allows one to probe di¡erent regions of the
C
Fig. 3. The reduction of NS EPR signal intensity following the
addition of Fe(II) is indicative of lipid peroxidation. After incu-
bation with NS, synaptosomes were treated with 30 WM Fe(II)
to initiate radical generation and a decrease in NS signal inten-
sity. In determining protective e¡ects, U101033E (or DMSO)
was incubated 30 min prior to addition of Fe(II). Overlapping
EPR spectra of (A) 5-NS and (B) 12-NS controls before and
after addition of Fe(II). The arrow indicates the loss of signal
intensity that is measured as an index of lipid oxidation. (C) In
the presence of Fe(II), 5-NS signal intensity is decreased by
41.7%. There is a similar loss of signal intensity after a pre-in-
cubation with 100 WM U101033E indicating a lack of protec-
tion against lipid peroxidation. (D) The decrease in 12-NS sig-
nal intensity by Fe(II) is 19.1%. In the presence of 100 WM
U101033E, the loss of signal intensity by iron-induced hydroxyl
radicals is essentially eliminated indicating protection against
lipid peroxidation. No decrease of NS intensity was observed in
the presence of U101033E or DMSO, while the decrease of sig-
nal intensity in oxidized, vehicle-treated samples were of similar
magnitude as that of oxidized controls. Dotted lines represent
unoxidized control values (n = 3^4; *P6 0.05; Student’s paired
t-test).
BBADIS 61931 19-5-00
C.M. Lauderback et al. / Biochimica et Biophysica Acta 1501 (2000) 149^161 153
membrane; 5-NS is close to the aqueous/lipid inter-
face and 12-NS is deeper within the bilayer [46].
The loss of 5-NS signal intensity in synaptosomes
after the generation of hydroxyl radicals suggests
that lipid oxidation has occurred which results in
the quenching of the paramagnetism of the NS probe
(Fig. 3A). No protection of lipid oxidation was af-
forded by the presence of U101033E as is evident by
a loss in 5-NS signal intensity comparable to that
observed in controls. In contrast to the 5-NS results,
100 WM U101033E, a concentration reported to be
e¡ective against lipid peroxidation [1], essentially
completely prevents the decrease of the 12-NS signal
induced by hydroxyl free radicals (Fig. 3B). This lat-
ter result is consistent with the proposed mechanism
of protection a¡orded by U101033E and other anal-
ogous pyrrolopyrimidines [1], as well as other reports
of protection from lipid peroxidation [26,33].
3.3. U101033E induces protein conformational
changes
In addition to protection against lipid peroxida-
tion, we investigated whether U101033E would pro-
tect synaptosomes against hydroxyl radical-induced
protein oxidation. The paramagnetic spin label
Mal-6 binds predominantly to protein thiol residues
giving information about protein conformations.
Mal-6 bound to protein thiols can be classi¢ed into
two main environments with respect to the motion of
the spin label: weakly (W)- and strongly (S)-immo-
bilized [43^46]. The motion of Mal-6 bound to W
sites is only weakly restricted, which is manifested
as narrow lines in the EPR spectrum. In contrast,
the Mal-6 bound to S sites have strongly hindered
motion, which is manifested as broadened lines in the
Fig. 4. The pyrrolopyrimidine U101033E induces conformation-
al changes in synaptosomal membrane proteins. Increasing con-
centrations of U101033E induce changes in protein conforma-
tion as deduced from decreases in the W/S ratio (n = 10;
*P6 0.001; **P6 0.0001; Student’s paired t-test).
Fig. 5. Fe(II)-induced hydroxyl radicals change synaptosomal
protein conformation and the magnitude of change is lessened
by 100 WM U101033E. (A) After treatment with Fe(II), a de-
crease in the W/S ratio occurs in samples pretreated with 1%
DMSO. A pretreatment of 100 WM U101033E causes a similar
decrease in the W/S ratio, while only a small further decrease is
observed after these U101033E-treated samples were treated
with Fe(II). (Both of these changes are signi¢cant from vehicle-
treated, unoxidized control.) (B) A normalization of the data in
(A) to their respective controls reveals a signi¢cant di¡erence in
the decrease of the W/S ratio after oxidation that is dependent
on the presence or absence of U101033E. Dotted line represents
normalized control values. Black bars represent unoxidized
samples whereas gray bars represent oxidized samples (n = 6;
*P6 0.0001 with respect to unoxidized vehicle; **P6 0.01 with
respect to both oxidized vehicle and unoxidized, U101033E-
treated samples; Student’s paired t-test).
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EPR spectrum. The resulting intensities of the re-
spective W and S peaks of the MI = +1 low-¢eld
resonance line give rise to the W/S ratio, which is
highly sensitive to protein conformational changes
[3,28,42^46]. Decreased values of the W/S ratio arise
from increased protein^protein interactions or de-
creased segmental motion of spin labeled proteins
and are lowered in synaptosomes following protein
oxidation [3,16,28,30,42].
Even in the absence of Fe(II), 100 WM U101033E
caused a signi¢cant 12.0% decrease (P6 0.001) in the
W/S ratio, while lower concentrations induced insig-
ni¢cant changes from control values that were sim-
ilar in magnitude to those induced by the vehicle
(Fig. 4). This result suggests that U101033E induces
physical changes in synaptosomal protein structure.
The decrement of W/S in samples that had been in-
cubated with the drug (100 WM) were of similar mag-
nitude to those changes seen in vehicle-treated sam-
ples that received oxidative treatments (Fig. 5A).
There seems to be no di¡erence in the W/S ratio in
oxidized samples pretreated with U101033E when
compared to oxidized samples pretreated with vehicle
only. However, there is a signi¢cant di¡erence
(P6 0.01) in Fe(II)-induced decrease in the W/S ratio
when samples in Fig. 5A are normalized to their
respective controls (Fig. 5B). These data suggest
that U101033E initiates some physical changes in
protein structure in the absence of an additional oxi-
dative stimulus, but that the drug partially prevents
further radical-induced damage, presumably by way
of its radical-scavenging ability.
3.4. Analysis of protein carbonyls
The incorporation of carbonyl groups into a pro-
tein backbone or side chains has become widely rec-
ognized as a marker of increased protein oxidation
[47,53]. Sensitive immunochemical methods for the
analysis of protein carbonyl formation in the pres-
ence of oxidative environments are available and
were used in this study to determine the e¡ect
U101033E had on hydroxyl radical-induced increases
in protein carbonyls. Immunoblot analysis indicates
that U101033E, in the absence of additional oxida-
tive stimulation, promotes the formation of protein
carbonyls in a concentration dependent manner (Fig.
6). At a concentration of 100 WM, U101033E in-
Fig. 6. The induction of protein carbonyls results after incuba-
tion of synaptosomes with U101033E. Increasing concentrations
of U101033E result in the oxidation of proteins, which is mani-
fested as protein carbonyls. Dotted line represents untreated
control values (n = 5^6; *P6 0.01; **P6 0.001; Student’s
paired t-test).
Fig. 7. A Coomassie Blue stained polyacrylamide gel indicates
U101033E-induced protein^protein cross-linking in synapto-
somes incubated at high concentrations (10 mM) of the drug.
The arrow indicates high molecular weight aggregates in sam-
ples treated with U101033E (D) that are not seen in control (C)
or vehicle (V)-treated samples. A concomitant loss of several
smaller molecular weight proteins is apparent in samples treated
with the drug.
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duced a 19.9% increase (P6 0.01) in synaptosomal
protein carbonyl groups and at extremely high con-
centrations caused an increase in protein cross-link-
ing that resulted in high molecular weight aggregates
and a concomitant loss of lower molecular weight
proteins (Fig. 7). Increased oxidation leads to
changes in protein structure [54], and these current
results are consistent with the e¡ects U101033E has
on protein conformation determined by EPR: in-
creased protein aggregation leads to decreased seg-
mental motion and correspondingly to decreased W/S
ratios of Mal-6 labeled proteins. In the presence of
generated free radicals, samples pretreated with
U101033E seemed to show no protection from car-
bonyl formation when compared to untreated con-
trols (Fig. 8A). However, when normalized to its
respective control, a pretreatment of 100 WM
U101033E eliminates any additional hydroxyl radi-
cal-induced protein oxidation (Fig. 8B). These data,
in agreement with our protein conformational stud-
ies, suggest that the radical scavenging abilities of
U101033E do protect the proteins from damage,
but only after the proteins have been altered by the
drug itself.
4. Discussion
The pyrrolopyrimidines have been proposed as po-
tent lipid peroxidation inhibitors and have proven to
be e¡ective protectants in several di¡erent models [1].
For example, several pyrrolopyrimidine variants, in-
cluding U101033E, have a¡orded protection in vari-
ous models of ischemia/reperfusion as measured by
infarct area [1,35^37] and neurological recovery
[1,35,36]. U101033E protects against hydroxyl radi-
cal-induced lipid peroxidation and peroxynitrite tox-
icity in cultured neurons [27] and prevents peroxyni-
trite-induced tyrosine nitration and Fe (II)/EDTA-
induced HNE formation in human erythrocyte mem-
branes [33,34]. Although U101033E has provided sig-
ni¢cant protection against a variety of insults, its
mechanism of action remains to be de¢ned.
The present study demonstrates the radical scav-
enging ability of U101033E as assessed by an aque-
ous cell-free EPR spin trapping assay (Fig. 2). A
decreased amount of PBN-radical adduct formation,
manifested as a decrease in EPR signal intensity, was
observed in the presence of U101033E. There was an
approximate two-fold decrease in signal intensity for
every mole of U101033E in samples with concentra-
tions less than the 30 WM of hydroxyl radicals pro-
duced. That the decrease in signal intensity was ap-
proximately double the expected value is consistent
with the antioxidative mechanism of U101033E pro-
posed by Hall et al. [1], which involves initial radical
quenching by electron donation and secondary radi-
cal trapping.
It is plausible that the DMSO in which the drug is
Fig. 8. Protein oxidation that occurs in the presence of Fe(II)-
induced hydroxyl radicals is lessened by the presence of 100
WM U101033E. (A) After treatment with Fe(II), an increase in
the protein carbonyl content occurs in synaptosomes pretreated
with 1% DMSO. A pretreatment of 100 WM U101033E alone
causes a 20.3% increase in carbonyl formation, while only a
small further increase is observed after U101033E-treated syn-
aptosomes were treated with Fe(II). (B) A normalization of the
data in (A) to their respective controls reveals di¡erences in
Fe(II)-induced increases in protein oxidation that is dependent
on the presence or absence of U101033E. Dotted line represents
vehicle-treated (A) or normalized control values (B). Black bars
represent samples before oxidation with Fe(II), while gray bars
represent samples after oxidative treatment (n = 3).
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delivered interferes with the determination of hy-
droxyl radical trapping by U101033E in this assay.
DMSO, which has been shown to be a radical scav-
enger [55], is in signi¢cant molar excess (140 mM) as
compared to PBN (10 mM). The hydroxyl radical is
extremely reactive and its reactivity is limited only by
di¡usion and, therefore, the hydroxyl radicals pro-
duced conceivably could react with DMSO before
they react with PBN or U101033E. In fact, the
DMSO-derived radical formed in the presence of hy-
droxyl radicals has been shown to react with PBN
[56]. The coupling constants from our spin trapping
experiments are equivalent to those of a DMSO-de-
rived radical and, in this scenario, the elimination of
signal by the drug would be due to the scavenging of
DMSO radicals. In all spin trapping experiments
conducted in this study the DMSO concentration
was held constant, yet the EPR signal decreased
with increasing drug concentration. Therefore it is
the drug, and not DMSO, that is responsible for
the decrement in the observed signal, i.e. the drug
is a potent radical scavenger.
The NS reduction model of lipid peroxidation is a
highly sensitive measure of lipid oxidation [14,29,52].
EPR spin labeling directly measures the presence of
stable free radical species, while the reduction of the
NS signal intensity must involve some transient free
radical species, likely either a carbon-centered or lip-
id peroxyl radical in these experiments, that react
with the paramagnetic center of the spin label. The
production of hydroxyl radicals will, by hydrogen
atom abstraction, initiate the propagation of lipid
radicals within the bilayer. These lipid radicals, by
reacting with molecular oxygen, can then form lipid
peroxides and hydroperoxides, which perturb mem-
brane structure and function [46,57] and have been
implicated in signal transduction processes that may
result in apoptotic cell death [58,59]. Lipid peroxides
are able to form, through various reactions and re-
arrangements, a multitude of lipid peroxidation
products, including HNE [10]. Di¡erences in lipid
structure, e.g. sites of unsaturation, result in di¡erent
rates of lipid peroxidation [57]. Unsaturated sites are
susceptible to peroxidation, which is attributed to
increased stability of the allylic carbon radical
through conjugation and thus have a longer lifetime
with which to react with oxygen. The di¡erence in
position of the nitroxide spin label on the stearic acid
acyl chain allows for the determination of radical
scavenging close to the phopholipid head groups
(5-NS) or deeper within the bilayer (12-NS), the lat-
ter near the most common sites of unsaturation. The
U101033E-mediated prevention of hydroxyl radical-
induced signal intensity loss in the 12-NS, but not
the 5-NS system, suggests that U101033E may be
localized in the membrane. This localization leads
to the scavenging of radicals in an area of the mem-
brane where HNE and other lipid peroxidation prod-
ucts are likely to be formed [60], but probably not
closer to the lipid/aqueous interface.
Protein oxidation results in altered protein struc-
ture and function [54], that causes changes in enzy-
matic activity [53,54,61] and loss of cellular homeo-
static control that ultimately leads to cellular
dysfunction [62]. Because protein oxidation occurs
in such oxidative events as ischemia [63] and due to
the known protection of the pyrrolopyrimidines
against ischemia [1], we reasoned that U101033E
may prevent the oxidation of proteins. However, in
our hands, U101033E induces protein oxidation and
conformational changes when incubated in synapto-
somal preparations (Fig. 6). This e¡ect increases with
increasing concentration of the drug while promoting
protein^protein cross-linking at extreme (10 mM)
concentrations (Fig. 7). These excessive concentra-
tions are unlikely to be used in in-vivo models where
protection is a¡orded at much lower doses [1], but
may be important in determining the mechanism of
action of U101033E; i.e. electron donation by
U101033E may account for its oxidative e¡ects on
these proteins. Further, protein conformational
changes, resulting in changes in the orientation rate
of protein-bound Mal-6 residues, have been previ-
ously correlated with increases in protein carbonyl
formation [3,28,40,63] and are similar to our current
¢ndings. The pro-oxidant activity of U101033E may
also play a role in its e¡ects on synaptosomal protein
conformations. However, these questions were not
directly addressed in this study.
At ¢rst glance our results seem to suggest that
U101033E has little protective e¡ect against oxida-
tive damage to synaptosomal proteins. However,
when determining whether U101033E protected syn-
aptosomal proteins from hydroxyl radical-induced
damage, samples were pre-incubated with the drug
before exposure to oxidation. Thus, any changes in
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protein carbonyl content or conformation induced by
U101033E may have occurred prior to the addition
of oxidants. After normalizing the data to each re-
spective control, it was evident that Fe(II)-dependent
protein oxidation in the presence of U101033E was
di¡erent from untreated, oxidized controls (Fig. 8B).
In similar fashion, after the initial change induced by
U101033E, only small changes in protein conforma-
tion take place after incubation with oxidants (Fig.
5B). This result suggests that U101033E does parti-
ally protect against hydroxyl radical-induced protein
oxidation, even if the drug itself induces protein ox-
idation.
An aldehydic product of lipid peroxidation, HNE,
covalently modi¢es proteins inducing changes in con-
formation [64] and cross-linking [65,66], while caus-
ing diminished enzymatic activity [67^70]. Indeed,
the cytotoxicity of HNE is well established
[10,71,72]. Because levels of HNE, both free and
bound, are increased in AD [19^23] and because
AL has been shown to increase the levels of HNE
in cells and synaptosomes [15,17], it has been sug-
gested that HNE partially mediates the toxicity of
AL [15^17]. Further, HNE has been shown to be
increased in the neuronal damage associated with
an ischemic injury. For example, Yoshino et al. dem-
onstrated HNE-positive immunostaining within the
infarcted area that results from ischemia/reperfusion
injury [73]. Considering the evidence supporting a
role for HNE and lipid peroxidation in neurodegen-
eration, therapeutics that target the protection of
membrane lipids in disorders associated with oxida-
tive stress may prove most bene¢cial.
These current results support the notion that
U101033E is a potent free radical scavenger that at-
tenuates lipid peroxidation occurring deep within the
lipid bilayer. That U101033E can prevent the peroxi-
dation of lipids, and likely HNE formation, in syn-
aptosomes has profound relevance for neuronal de-
generation, which is thought to originate at the
synapse [74]. Indeed, the prevention of HNE forma-
tion and subsequent toxicity may be a key to the
protection a¡orded by U101033E. Levels of HNE
are increased after an ischemic insult [73], neuronal
cell death in ischemia is apoptotic [75,76] and HNE
has been shown to mediate oxidative stress-induced
apoptosis [77]. These studies also support the notion
that U101033E, possibly by way of its radical donat-
ing ability, initiates protein oxidation. As stated
above, the concentrations of U101033E that result
in oxidation or cross-linking of proteins are unlikely
in a clinical scenario, however, one must remain cau-
tious of these e¡ects. This oxidation may result in the
inactivation of proteins and enzymes critical for a
neuronal response to injury, and in this sense
U101033E may be more problematic than therapeu-
tic. Thus, one must weigh the bene¢ts of protection
from lipid peroxidation against the possibility of in-
creased protein oxidation when considering
U101033E as a potential drug candidate.
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